title: Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy.
abstract: Hollow mesoporous silica nanoparticle (HMSN) has recently gained increasing interests due to their tremendous potential as an attractive nano-platform for cancer imaging and therapy. However, possibly due to the lack of efficient in vivo targeting strategy and well-developed surface engineering techniques, engineering of HMSN for in vivo active tumor targeting, quantitative tumor uptake assessment, multimodality imaging, biodistribution and enhanced drug delivery have not been achieved to date. Here, we report the in vivo tumor targeted positron emission tomography (PET)/near-infrared fluorescence (NIRF) dual-modality imaging and enhanced drug delivery of HMSN using a generally applicable surface engineering technique. Systematic in vitro and in vivo studies have been performed to investigate the stability, tumor targeting efficacy and specificity, biodistribution and drug delivery capability of well-functionalized HMSN nano-conjugates. The highest uptake of TRC105 (which binds to CD105 on tumor neovasculature) conjugated HMSN in the 4T1 murine breast cancer model was ~10%ID/g, 3 times higher than that of the non-targeted group, making surface engineered HMSN a highly attractive drug delivery nano-platform for future cancer theranostics.
authors.affiliation: 1] Department of Radiology, University of Wisconsin - Madison, WI, USA [2].
authors.forename: Feng
authors.initials: F
authors.lastname: Chen
authors.affiliation: 1] Department of Radiology, University of Wisconsin - Madison, WI, USA [2].
authors.forename: Hao
authors.initials: H
authors.lastname: Hong
authors.affiliation: Materials Science Program, University of Wisconsin - Madison, WI, USA.
authors.forename: Sixiang
authors.initials: S
authors.lastname: Shi
authors.affiliation: Materials Science Program, University of Wisconsin - Madison, WI, USA.
authors.forename: Shreya
authors.initials: S
authors.lastname: Goel
authors.affiliation: Department of Medical Physics, University of Wisconsin - Madison, WI, USA.
authors.forename: Hector F
authors.initials: HF
authors.lastname: Valdovinos
authors.affiliation: Department of Medical Physics, University of Wisconsin - Madison, WI, USA.
authors.forename: Reinier
authors.initials: R
authors.lastname: Hernandez
authors.affiliation: TRACON Pharmaceuticals, Inc., San Diego, CA, USA.
authors.forename: Charles P
authors.initials: CP
authors.lastname: Theuer
authors.affiliation: Department of Medical Physics, University of Wisconsin - Madison, WI, USA.
authors.forename: Todd E
authors.initials: TE
authors.lastname: Barnhart
authors.affiliation: 1] Department of Radiology, University of Wisconsin - Madison, WI, USA [2] Materials Science Program, University of Wisconsin - Madison, WI, USA [3] Department of Medical Physics, University of Wisconsin - Madison, WI, USA [4] University of Wisconsin Carbone Cancer Center, Madison, WI, USA [5].
authors.forename: Weibo
authors.initials: W
authors.lastname: Cai
mesh_terms: D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000493:pharmacokinetics*; D015703:Antigens, CD / Q000378:metabolism*; D045744:Cell Line, Tumor; D003460:Crystallization / Q000379:methods; D004357:Drug Synergism; D000071063:Endoglin; D006801:Humans; D008422:Materials Testing; D053769:Nanocapsules / Q000737:chemistry* / Q000648:ultrastructure*; D058726:Nanoconjugates / Q000737:chemistry / Q000648:ultrastructure; D058608:Nanopores / Q000648:ultrastructure; D009374:Neoplasms, Experimental / Q000737:chemistry / Q000378:metabolism*; D010316:Particle Size; D016062:Porosity; D011956:Receptors, Cell Surface / Q000378:metabolism*; D012822:Silicon Dioxide / Q000737:chemistry*; D013499:Surface Properties
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; C064206:ENG protein, human; D000071063:Endoglin; D053769:Nanocapsules; D058726:Nanoconjugates; D011956:Receptors, Cell Surface; D012822:Silicon Dioxide; C579557:carotuximab